Abstract:LSD1 and HDAC are physical and functional related to each other in various human cancers and simultaneous pharmacological inhibition of LSD1 and HDAC exerts synergistic anti-cancer effects. In this work, a series of novel LSD1/HDAC bifunctional inhibitors with a styrylpyridine skeleton were designed and synthesized based on our previously reported LSD1 inhibitors. The representative compounds 5d and 5m showed potent activity against LSD1 and HDAC at both molecular and cellular level and displayed high selectivity against MAO-A/B. Moreover, compounds 5d and 5m demonstrated potent antiproliferative activities against MGC-803 and HCT-116 cancer cell lines. Notably, compound 5m showed superior in vitro anticancer potency against a panel of gastric cancer cell lines than ORY-1001 and SP-2509 with IC<sub>50</sub> values ranging from 0.23 to 1.56 μM. Compounds 5d and 5m significantly modulated the expression of Bcl-2, Bax, Vimentin, ZO-1 and E-cadherin, induced apoptosis, reduced colony formation and suppressed migration in MGC-803 cancer cells. In addition, preliminary absorption, distribution, metabolism, excretion (ADME) studies revealed that compounds 5d and 5m showed acceptable metabolic stability in human liver microsomes with minimal inhibition of cytochrome P450s (CYPs). Those results indicated that compound 5m could be a promising lead compound for further development as a therapeutic agent in gastric cancers via LSD1 and HDAC dual inhibition.

Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships

Synthetic Routes And Biological Evaluation Of Largazole And Its Analogues As Potent Histone Deacetylase Inhibitors

Synthesis and biological evaluation of largazole zinc-binding group analogs

Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of N-heterocyclic carbene mediated acylations in complex molecule synthesis.

Biological Evaluation of New Largazole Analogues: Alteration of Macrocyclic Scaffold with Click Chemistry

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Total Synthesis and Biological Evaluation of Largazole and Derivatives with Promising Selectivity for Cancers Cells.

Promising natural lysine specific demethylase 1 inhibitors for cancer treatment: advances and outlooks

Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer

Design and Synthesis of HDAC Inhibitors to Enhance the Therapeutic Effect of Diffuse Large B-cell Lymphoma by Improving Metabolic Stability and Pharmacokinetic Characteristics.

Suberoylanilide Hydroxamic Acid Analogs with Heteroaryl Amide Group and Different Chain Length: Synthesis and Effect on Histone Deacetylase

Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities Against Tumor Growth and Metastasis

Design, Synthesis and Biological Evaluation of Novel Isoindolinone Derivatives As Potent Histone Deacetylase Inhibitors.

Progress in the Research of Structure-Activity Relationship of the Benzamide Class of Histone Deacetylase Inhibitors

Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities

Design, Synthesis, and Antitumor Evaluation of Histone Deacetylase Inhibitors with L-Phenylglycine Scaffold

Design, Synthesis and Biological Evaluation of Isoquinoline-Based Derivatives As Novel Histone Deacetylase Inhibitors

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Strategies in Developing Promising Histone Deacetylase Inhibitors.

Key structural requirements of benzamide derivatives for histone deacetylase inhibition: design, synthesis and biological evaluation

Development of N-Hydroxycinnamamide-Based Hdac Inhibitors with Improved Hdac Inhibitory Activity and in Vitro Antitumor Activity